<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Biogen Idec Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/biogen-idec-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech</title>
		<link>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986</link>
		<comments>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:57:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Facet Biotech Corporation]]></category>
		<category><![CDATA[FACT]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15986</guid>
		<description><![CDATA[After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at approximately $356 million. The tender offer will expire at 12:00 midnight, ET, on Oct. 19, 2009. As a reminder, Biogen had initially approached Facet with an offer of $15 per share on Aug. 17, 2009. However, Facet did not accept the offer as the company believed that it was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/biib-biogen-launches-hostile-bid-for-partner-facet-biotech/15986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Releases Encouraging Data for Pixantrone</title>
		<link>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570</link>
		<comments>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15570</guid>
		<description><![CDATA[Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone for the treatment of patients with advanced, relapsed or refractory, aggressive non-Hodgkin&#8217;s lymphoma (NHL). The original trial compared pixantrone with standard chemotherapy; the results of which were reported last November. The company completed filing its rolling New Drug Application (NDA) in June this year and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Apr 23, 2010. The follow-up trial conducted over a period of 18 months found improved results for patients on pixantrone compared to the control group. Based on the parameters of complete response (25.7% vs. 7.1% in control group), overall response rate (40% vs. 14.3%) and progression free survival (5.6 months vs. 2.6 months), the pixantrone data were better ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) Elan Redesigns Johnson &amp; Johnson Deal to Satisfy Biogen</title>
		<link>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263</link>
		<comments>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263#comments</comments>
		<pubDate>Wed, 16 Sep 2009 17:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15263</guid>
		<description><![CDATA[We believe the dispute between Elan Corp. (ELN) and its US partner Biogen Idec (BIIB) over multiple-sclerosis drug Tysabri has been resolved at last. The row started when Elan signed a deal with Johnson &#38; Johnson (JNJ) last July. But now, the two companies have amended this deal to drop the terms involving Tysabri. J&#38;J will now pay $885 million, down from the previously announced $1 billion for an 18.4% stake in Elan. However, J&#38;J’s $500 million investment for a majority stake in the Alzheimer&#8217;s disease pipeline remains unchanged. Although Elan claimed that the new terms will restore its &#8216;unintended breach&#8217; of contract with Biogen Idec related to Tysabri rights, we are yet to know whether its US partner has accepted this argument. Biogen and Elan have a 50-50 partnership ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/eln-elan-redesigns-johnson-johnson-deal-to-satisfy-biogen/15263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme&#8217;s Multiple Sclerosis Drug Shows Promise</title>
		<link>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277</link>
		<comments>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:27:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15277</guid>
		<description><![CDATA[On Friday, Genzyme Corp. (GENZ) presented encouraging four-year follow-up phase II data on alemtuzumab, which is being developed for the treatment of multiple sclerosis (MS). Results showed durable reductions in relapse rate and sustained accumulation of disability even three years after patients received their last course of alemtuzumab. The company presented these efficacy and safety data at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis in Germany. This CAMMS223 study was conducted in early, relapsing-remitting MS patients, who were randomized to receive either alemtuzumab or Pfizer/Serono&#8217;s (PFE) Rebif. Patients taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 72% and the risk of sustained accumulation of disability by 73% compared to patients receiving Rebif. Additionally, the annualized relapse rate and disability risk ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/genz-genzymes-multiple-sclerosis-drug-shows-promise/15277/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Maintains Facet Biotech Offer</title>
		<link>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795</link>
		<comments>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795#comments</comments>
		<pubDate>Thu, 10 Sep 2009 02:38:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14795</guid>
		<description><![CDATA[Yesterday, Biogen Idec (BIIB) reiterated its intention to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, even though Facet turned down the offer saying it was not in the best interests of its shareholders. The offer price represents a 64% premium to Facet’s closing price on September 3, 2009. The deal is valued at approximately $356 million. Biogen had initially approached Facet with an offer of $15 per share on August 17, 2009. However, Facet did not accept the offer as the company believed that the offer price was not in the best interests of its shareholders. Soon thereafter, Facet entered into a collaboration with Trubion Pharmaceuticals (TRBN), a move that was criticized by Biogen. According to Biogen, the Trubion deal led to a reduction in Facet’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/biib-biogen-maintains-facet-biotech-offer/14795/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Fails to Impress</title>
		<link>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608</link>
		<comments>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608#comments</comments>
		<pubDate>Tue, 08 Sep 2009 23:26:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14608</guid>
		<description><![CDATA[We were disappointed to hear that the US Food and Drug Administration (FDA) has granted standard review status to Cell Therapeutics’ (CTIC) pixantrone for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). The company completed filing its rolling New Drug Application (NDA) in June this year and asked for priority review. Priority review would have reduced the approval period by four months. Pixantrone, currently under a ten-month standard review, has been assigned a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010. NHL is a cancer that affects lymphocytes, a type of white blood cell that helps fight infection. Since pixantrone had already received fast-track status from the FDA, we were expecting a priority review for the drug. In June, Cell Therapeutics presented encouraging results from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Court Rules in Favor of Biogen Idec</title>
		<link>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470</link>
		<comments>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:00:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14470</guid>
		<description><![CDATA[Biogen Idec (BIIB) received good news yesterday in the form of a favorable court ruling in its dispute with partner Elan Corp. PLC (ELN) regarding their 10-year collaboration for multiple sclerosis drug Tysabri. As a reminder, Elan took Biogen to court in early August 2009 in order to prevent Biogen from gaining control over Tysabri. Soon after, Johnson &#38; Johnson (JNJ) signed an agreement to acquire an 18.4% stake in Elan for $1.5 billion, Biogen claimed that Elan has breached the collaboration agreement between the two companies for Tysabri. In addition to its 18.4% stake in Elan and a majority stake in Elan’s Alzheimer&#8217;s disease pipeline, J&#38;J reportedly received an option to acquire Elan’s 50% stake in Tysabri, if there is a change in ownership at Biogen. Yesterday’s ruling found ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/biib-court-rules-in-favor-of-biogen-idec/14470/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) Medicines Company&#8217;s Angiomax Anti-Clotting Drug Promising</title>
		<link>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136</link>
		<comments>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:44:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Co]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14136</guid>
		<description><![CDATA[Medicines Co. (MDCO) yesterday presented encouraging results from its landmark HORIZONS-AMI study on anti-clotting drug, Angiomax. The company stated that treatment with Angiomax resulted in improved survival rates in patients who had suffered from the most severe form of heart attack and received angioplasty. Approximately 3,600 patients with ST elevation myocardial infarction (STEMI), the most severe form of acute heart attack, and undergoing primary percutaneous coronary intervention (PCI), commonly known as angioplasty, were studied in the trial. Patients were randomized to receive Angiomax with provisional use of a glycoprotein IIb/IIIa inhibitor or heparin plus a glycoprotein IIb/IIIa inhibitor. Results showed that Angiomax reduced cardiac-related death by 43%, improved overall survival by 27% and reduced major bleeding complications by 39%, compared to the standard of care. Angiomax showed an absolute reduction ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/mdco-gpi-medicines-companys-angiomax-anti-clotting-drug-promising/14136/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRBN) Trubion Pharmaceuticals &amp; Facet Biotech to Jointly Develop and Market Leukemia Drug</title>
		<link>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953</link>
		<comments>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953#comments</comments>
		<pubDate>Mon, 31 Aug 2009 21:08:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TRBN]]></category>
		<category><![CDATA[Trubion Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13953</guid>
		<description><![CDATA[On Friday, Trubion Pharmaceuticals, Inc. (TRBN) agreed to jointly develop and commercialize TRU-016 globally with Facet Biotech Corp. (FACT).  TRU-016 is undergoing early-stage studies for chronic lymphocytic leukemia (CLL). The deal requires Facet to make a $20 million upfront payment to Trubion coupled with an additional $176.5 million on the achievement of certain milestones. Further, Facet has agreed to buy 2.24 million shares of newly issued Trubion common stock for $10 million. The companies have agreed to contribute equally towards costs related to development, commercialization and promotional activities. All global operating profits will be shared equally. The TRU-016 program is focused on the development of a novel CD37-targeted therapy for B-cell malignancies, such as Non-Hodgkin&#8217;s lymphoma (NHL) and CLL. CD37 is a clinically validated target for the treatment of B-cell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/trbn-trubion-pharmaceuticals-facet-biotech-to-jointly-develop-and-market-leukemia-drug/13953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) FDA Approves Novartis MS Drug</title>
		<link>http://www.stockbloghub.com/2009/08/20/nvs-fda-approves-novartis-ms-drug/12922</link>
		<comments>http://www.stockbloghub.com/2009/08/20/nvs-fda-approves-novartis-ms-drug/12922#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:35:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12922</guid>
		<description><![CDATA[Earlier this week, the US Food and Drug Administration (FDA) approved Novartis Pharma’s (NVS) Extavia, a branded version of interferon beta-1b, which is used for the treatment of multiple sclerosis (MS). Novartis obtained the rights to seek approval for its own branded version of interferon beta-1b through agreements signed with Bayer Schering, which markets Betaseron. MS is a chronic autoimmune disease in which the body&#8217;s immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain. As a result, persons afflicted with the disease experience problems with muscle control and strength, vision, balance, sensation and mental function. Extavia has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. It is also indicated for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/nvs-fda-approves-novartis-ms-drug/12922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec, Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/06/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy-2/5144</link>
		<comments>http://www.stockbloghub.com/2009/04/06/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy-2/5144#comments</comments>
		<pubDate>Mon, 06 Apr 2009 22:56:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5144</guid>
		<description><![CDATA[Biogen Idec, Inc.&#8217;s (BIIB) share price has launched a strong rally in the last four weeks in response to bullish earnings projections and another strong quarter. Fourth-Quarter Results Biogen reported strong fourth-quarter results in early February that were ahead of expectations. Revenue was up 20% to $1.1 billion. Earnings came in at 91 cents per share, 3 cents ahead of the consensus estimate. This is the fourth time in four quarters that Biogen has surprised and beat estimates, having done so by an average of 5 cents, or 6%. Estimates Advance The current-year estimate continues to advance Incorporatedreasing 7 cents in the last 60 days to $4.06 per share. The Chart As previously mentioned, shares of BIIB have been rallying for most of the last month, humming higher to a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/06/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy-2/5144/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec, Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/30/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy/4848</link>
		<comments>http://www.stockbloghub.com/2009/03/30/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy/4848#comments</comments>
		<pubDate>Mon, 30 Mar 2009 19:42:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4848</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) estimates are climbing as the company&#8217;s quarterly earnings announcement quickly approaches. Estimates are Up Biogen is set to announce first quarter results on Apr 15. Analysts have been raising estimates at a steady rate over the past 90 days. Full-year estimates for 2009 are $4.06, up from $3.94 in that time span. The consensus for 2010 is now $4.27, up from $4.15. These projections, if met, represent 13% year-over-year growth for 2009 and another 5% in 2010. Upcoming Surprise? As part of the Zacks Rank, surprise history plays an important roll in a stock&#8217;s performance. Those companies that have reported earnings surprise in previous quarter are more likely to beat estimates again than companies who have not. That being said, Biogen has out paced Wall Street ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/30/biib-biogen-idec-inc-aggressive-growth-zacks-rank-buy/4848/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec &#8211; third-quarter results that included a 64% spike in earnings</title>
		<link>http://www.stockbloghub.com/2009/01/20/biogen-idec-third-quarter-results-that-included-a-64-spike-in-earnings/2227</link>
		<comments>http://www.stockbloghub.com/2009/01/20/biogen-idec-third-quarter-results-that-included-a-64-spike-in-earnings/2227#comments</comments>
		<pubDate>Wed, 21 Jan 2009 00:42:04 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2227</guid>
		<description><![CDATA[Biogen Idec Inc. (BIIB) shares continue to climb as the company&#8217;s next earnings announcement quickly approaches. Biogen is looking for its fifth consecutive surprise on Feb 6. Company Description Biogen Idec, Inc. is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The company&#8217;s first commercial product, Rituxan, and most advanced product candidate, Zevalin, are for use in the treatment of certain B-cellnon-Hodgkin&#8217;s lymphomas. Biogen is also developing products for the treatment of various autoimmune diseases, such as psoriasis, rheumatoidarthritis and lupus. Earnings Spike On Oct 21 Biogen reported third-quarter results that included a 64% spike in earnings. Earnings per share came in at 95 cents, up from 58 cents one year ago. Revenues were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/20/biogen-idec-third-quarter-results-that-included-a-64-spike-in-earnings/2227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

